1 day Ago By [email protected] (MENAFN)
This innovative tech collaboration addresses emotional, logistical and financial challenges associated with international clinical trial recruitment, accelerating access to groundbreaking treatments globally. AMSTERDAM, April 15, 2025 /PRNewswire/ -- myTomorrows , a global health technology company connecting patients with all possible treatment options, has announced a new partnership with Scout , a leader in services and technology for the biopharmaceutical industry. Together, they aim to streamline and enhance cross-border patient recruitment for clinical trials.
This will be achieved by addressing complex financial and logistical arrangements on behalf of patients, families, and caregivers, ensuring they are spared the challenges typically associated with accessing potential pre-approval treatments. Cross-border clinical research faces significant hurdles, from fragmented information systems and regulatory differences to complex visa and data privacy processes. Coupled with linguistic and cultural barriers, these challenges can impact communication and create delays.
For rare disease trials or studies with strict eligibility criteria, they often prolong recruitment timelines, raise costs, and limit patient diversity, hindering access to developing therapies. Through this partnership, the patient journey is optimized by connecting trial matching to personalized domestic and cross-border support services. While myTomorrows' Patient Navigator team supports patients with initial trial option identification and pre-screening, the Scout Clinical service line offers services such as travel arrangements, expense reimbursements, pre-funded debit cards for out-of-pocket costs, and accommodation support, including short-term lodging and long-term housing for relocated patients and families.
Visa and entry and exit assistance further reduce the burden on patients, families, and caregivers. "Our partnership with myTomorrows is a win-win for all stakeholders across the clinical trial ecosystem," said Scout CEO Moisha Platto. "By addressing key barriers early, sites can efficiently manage international patient intake and expand their reach.
Patients will benefit from a clearer understanding of the process and access to a wider range of potential treatment options. This approach simplifies enrollment and enhances the overall experience for patients and their families, improving retention rates and ensuring comprehensive support every step of the way." The partnership will deliver services that combine advanced logistics and precision AI to revolutionize recruitment outcomes.
Scout expands global patient reach, diversifies enrollment pools, and streamlines trial operations, making it easier for researchers to meet recruitment goals. Meanwhile, myTomorrows' AI platform identifies potentially eligible trial options within seconds, delivering a 90% reduction in eligibility criteria checking time for physicians compared to manual processes-alleviating administrative burden and enhancing screening efficiency. Together, they deliver faster, more effective recruitment while upholding international data protection regulations.
"By removing barriers and overcoming the geographic silos of traditional trials, we provide every patient, regardless of location or personal circumstances, with a real opportunity to participate" said Michel van Harten, MD, CEO of myTomorrows. "By partnering with Scout Clinical, we aim to make clinical research more viable and accessible, by connecting to trial sites beyond their immediate proximity, whether across borders or within large domestic regions. Our inventive approach directly addresses the industry's critical need to expand patient access whilst easing logistical burdens for patients and their families.
By breaking down these barriers we materially improve the patient journey and accelerate clinical research." The collaboration between these two organizations marks a pivotal step in advancing global clinical research, ensuring that patients worldwide have greater access to potentially life-changing treatments. About myTomorrows: myTomorrows is a global healthtech company dedicated to breaking down barriers for patients seeking treatment options.
To make this a reality, the company has built a unique and powerful proprietary technology that conducts a comprehensive and accurate search of clinical trials, and where appropriate, Expanded Access Programs, from global public registries. This functionality efficiently connects patients, physicians, trial sites and BioPharma to simplify and accelerate access to drugs in development. Headquartered in Amsterdam with an office in New York City, myTomorrows has helped more than 15,300 patients and 2,400 physicians across 240+ sites in over 128 countries.
mytomorrows myTomorrows Media Contact: Kate Schoenstadt Headline Media [email protected] +972 54 777 6684 About Scout: Scout empowers the life sciences industry with people-first solutions: Scout Meetings, Scout Clinical, and Scout Academy. We specialize in face-to-face, virtual, and hybrid clinical meeting planning, patient payment, travel, and logistics support, and virtual collaboration and education. Since 1995, we've been a trusted partner in customer service, regulatory compliance, and project delivery for leading pharmaceutical and biotechnology companies.
Our deep understanding of international regulations and adaptable network of resources is built on operational experience in 109 countries. With white-glove attention to detail and a customizable, comprehensive range of services, Scout makes the complex easier. Visit scoutclinical .
Scout Media Contact: Erin Deneckere Scout [email protected] +1 972 503 6119 SOURCE myTomorrows and Scout Clinical MENAFN15042025003732001241ID1109430632 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
.
